연구용제품시약 > Chemical Reagent
[APExBIO한국공식대리점] Research Solutions for COVID-19
바이오클론
APExBIO는 Small molecule, Inhibitor, Peptide 등의
chemical 관련 제품을 직접 생산, 공급하는 브랜드입니다.
바이오클론(주)는
APExBIO의 한국공식독점대리점이며,
2015년부터 정부의 화학물질의 등록 및 평가 등에
관한 법률(화평법)에 의해 모든 화학물질을 한국환경공단에
신고, 허가 하에 안전하게 수입 공급하고 있습니다.
한국환경공단 신고허가없이 수입되거나 공식대리점이 아닌 무분별한 수입업자에 공급되어진 화학물질품목은 화평법에 의해 문제소지가 발생할수 있습니다 |
There is currently no specific medicine or treatment for diseases caused by SARS-CoV-2. To identify antiviral candidates, scientists are focused on drug repurposing and antiviral molecules screening from chemical libraries.
We offer efficient compound libraries to assist in the global efforts to develop novel drug candidates, such as FDA-approved Drug Library and Anti-Virus Compound Library.
We also offer reverse transcription and qPCR series to help efficiently detect SARS-CoV-2, and mRNA in vitro synthesis platform to support the development of mRNA vaccines.
Screening Libraries
Cat.No. | Product Name | Information |
L1021 | FDA-approved Drug Library | 1971 FDA-approved drugs |
L1022 | Bioactive Compound Library | 3317 bioactive compounds |
L1022P | Bioactive Compound Library Plus | 4417 bioactive compounds |
L1050 | Anti-Virus Compound Library | 264 anti-virus compounds |
L1039 | Natural Product Library | 550 natural products |
L1039P | Natural Product Library Plus | 1170 natural products |
L1027 | Anti-infection Compound Library | 367 anti-infection small molecules |
L1027P | Anti-infection Compound Library Plus | 663 anti-infection small molecules |
L1035 | Protease Inhibitor Library | 825 protease inhibitors |
L1026 | Neuronal Signaling Library | 556 neuronal signaling-related small molecules |
L1026P | Neuronal Signaling Compound Library Plus | 948 neuronal signaling-related small molecules |
L1024 | Kinase Inhibitor Library | 796 kinase inhibitors |
L1023 | Anti-cancer Compound Library | 1164 anti-cancer compounds |
L1023P | Anti-cancer Compound Library Plus | 1777 anti-cancer compounds |
L1025 | GPCR Compound Library | 677 GPCR-related small molecules |
L1029 | Epigenetics Compound Library | 328 epigenetics-related small molecules |
L1034 | PI3K/Akt/mTOR Compound Library | 178 PI3K/Akt/mTOR inhibitors |
L1041 | JAK/STAT Compound Library | 109 JAK/STAT inhibitors |
L1028 | Tyrosine Kinase Inhibitor Library | 369 tyrosine kinase inhibitors |
L1031 | Autophagy Compound Library | 486 autophagy-related compounds |
L1031P | Autophagy Compound Library Plus | 837 autophagy-related compounds |
L1032 | Metabolism-related Compound Library | 493 metabolism-related compounds |
L1032P | Metabolism-related Compound Library Plus | 1205 metabolism-related compounds |
L1036 | Apoptosis Compound Library | 643 apoptosis-related compounds |
L1038 | Histone Modification Library | 157 histone modification-related compounds |
L1040 | Stem Cell Compound Library | 169 stem cell-related compounds |
L1040P | Stem Cell Compound Library Plus | 280 stem cell-related compounds |
L1042 | Immunology/Inflammation Compound Library | 295 immunology/inflammation-related small molecules |
L1042P | Immunology/Inflammation Compound Library Plus | 806 immunology/inflammation-related small molecules |
L1043 | MAPK Inhibitor Library | 117 MAPK inhibitors |
L1048 | Inhibitor Library | 2525 inhibitors |
L1033 | DNA Damage/DNA Repair Library | 481 DNA Damage/DNA repair-related compounds |
L1037 | Cell Cycle Library | 449 cell cycle-related compounds |
L1045 | TGF-beta/Smad Compound Library | 88 TGF-beta/Smad inhibitors |
L1030 | Ion Channel Compound Library | 199 ion channel-related compounds |
L1030P | Ion Channel Compound Library Plus | 350 ion channel-related compounds |
L1044 | NF-κB Signaling Library | 73 NF-κB inhibitors |
L1044P | NF-κB Signaling Compound Library Plus | 178 NF-κB inhibitors |
L1046 | Anti-diabetic Compound Library | 110 anti-diabetic small molecules |
L1047 | Angiogenesis Library | 84 angiogenesis-related small molecules |
L1049 | Ubiquitination Compound Library | 144 ubiquitination compounds |
We also offer customized screening libraries that allow you to choose the compounds, the sizes, the quantities, the format (powder or solution) and plate map you want in the library.
1. Reverse Transcriptase, qPCR Series
qPCR amplification curve of SARS-CoV-2 S gene. The initial number of copies of template DNA: 10/20/200 copies. The DNA was quantified using 2X SYBR Green qPCR Master Mix (Cat. No. K1070).
qPCR amplification curve of human β-Action. RNA was extracted from 293A cells and diluted to 7 different concentrations (1μg/μl, 100ng/μl, 10ng/μl, 1ng/μl, 100pg/μl, 10pg/μl, 1pg/μl). Reverse transcription was performed using First-Strand cDNA Synthesis SuperMix (Cat. No. K1073) to obtain cDNA products. The cDNA was then quantified using 2X SYBR Green qPCR Master Mix (Cat. No. K1070).
Cat.No. | Product Name | Information |
K1070 | 2×SYBR Green qPCR Master Mix | 2X PreMix for quantifying target DNA or cDNA |
K1071 | Reverse Transcriptase | Thermally stable reverse transcriptase used to synthesize complementary DNA (cDNA) from an RNA template |
K1072 | First-Strand cDNA Synthesis Kit | Synthesize first-strand cDNA from purified poly(A)+ or total RNA |
K1073 | First-Strand cDNA Synthesis SuperMix | Reverse transcription reaction premixed solution for efficient synthesis of first-strand cDNA |
K1074 | RT SuperMix for qPCR | High efficiency reverse transcription reaction premixed solution for two-step RT-qPCR method |
K1046 | RNase Inhibitor, Murine | RNase Inhibitor, Murine specifically inhibits RNases A, B and C to protect RNA from degradation |
2. RNA In Vitro Synthesis Platform
An overview of the workflow developing mRNA vaccines against 2019-nCoV. Both receptor-binding domain of the spike protein (S-RBD) and Virus like particles (VLPs) were chosen as the antigen. Strategy one: Based on the mRNA in vitro transcription platform, SARS-CoV-2 S, M, E mRNA were synthesized in vitro and individually transfected into 293T cells by using lipofectamine 2000. Virus like particles (VLPs) were produced and used as the presenting antigen. VLPs synthesized by the host cells have the same posttranslational modifications as the native virus, which is an important factor determining the validity of an antigen. Strategy two: For the S-RBD antigen, the RBD domain of the S protein was also expressed in cells using in vitro transcription (IVT) mRNA. (Ref.1)
VLPs were visualized under an electron microscope. We observed particles with striking features of coronavirus. The outline of the envelope for most particles was clear, the spikes were visible. The average size of the particle is 70nm in diameter for the membrane envelope and 90nm when including the spikes, consistent with reported native 2019-nCoV virus. (Ref.1)
The trimeric structure of the extra-vesicular domain of the spike protein from SARS-CoV. The receptor-binding domain (RBD) was used as the antigen. Use mRNA to express the receptor-binding domain of the spike protein (S-RBD). The S glycoprotein is responsible for binding to the receptor through its RBD, enabling the virus to enter into target cells by fusing with cell membranes. The western blot analysis was used to confirm the expression of target proteins. (Ref.1)
Reference:
1.Towards an effective mRNA vaccine against 2019-nCoV: demonstration of virus-like particles expressed from a modified mRNA cocktail.
매주 금요일 4시 발주 1-2 주 소요
Homepage : www.bioclone.co.kr
한국독점대리점 바이오클론㈜
T) 02-2690-0058 F) 02-2690-0397
www.bioclone.co.kr
본 정보는 "바이오클론" (으)로 문의 바랍니다.